Steris (STE)

Health Care · $25.1B market cap · SEC CIK 0001757898

Next reports on Feb 2, 2027, with analysts expecting $2.83 in earnings per share.

52-week range $195.14 to $269.44. 5% below its 52-week high and 32% above its low.

The case for STE

• Generated $972M of free cash flow in FY2026, 16% of revenue.
• Revenue growing 8.4% year over year.
• Earnings per share up 25.3%.
• Has compounded revenue at 13.8% a year over five years.
• Pays a modest 1.0% dividend.

The case against

• Weakest against its peers: price/sales of 4.2× is higher than 57% of Health Care companies.
• Its weakest area is value (59/100): 31.1× earnings against a fair 26× for its growth, 4.2× sales, 3.9% free-cash yield.

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

The financials

The financials, five years deep

Pulled from Steris's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What Steris says it does

INTRODUCTION STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. We offer our Customers a unique mix of innovative products and services. These include: consumable products, such as detergents, endoscopy accessories, barrier products, instruments and tools; services, including equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair, laboratory testing, and outsourced reprocessing; capital equipment, such as sterilizers, surgical tables, and automated endoscope reprocessors; and connectivity solutions such as operating room (“OR”) integrati on. We operate and report our financial information in three reportable business segments: Healthcare, Applied Sterilization…

Risk factors STE lists in its 10-K

• Changes in economic climate may adversely affect us
• Compliance with multiple, and potentially conflicting, international laws and regulations, import and export limitations, anti-corruption laws, and exchange controls may be difficult, burdensome or expensive
• Healthcare Policy and Reimbursement
• Changes in healthcare policy or government and other third-party payor reimbursement levels to healthcare providers, or failure to meet healthcare reimbursement or other requirements, might negatively impact our business
• Product and Service Related Regulations and Claims
• Our products are subject to recalls and restrictions, even after receiving U.S. or foreign regulatory clearance or approval
• We may be adversely affected by product liability claims or other legal actions or regulatory or compliance matters
• Our business and financial condition could be adversely affected by difficulties in acquiring or maintaining a proprietary intellectual ownership position
• We may be adversely impacted by changes in tax laws or challenges to our tax positions, and our
• effective tax rate is uncertain and may vary from expectations, which could have a material impact on our results of operations and earnings per share
• Current economic and political conditions make tax rules in any jurisdiction subject to significant change
• Changes in tax treaties and trade agreements could negatively impact our costs, results of operations and earnings per share
• Legislation relating to the denial of U.S. federal or state governmental contracts to U.S. companies that redomicile abroad could adversely affect our business
• Our business environment is highly competitive, and if we fail to compete successfully, our revenues and results of operations may be negatively impacted
• Consolidations among our healthcare and pharmaceutical Customers may result in a loss of Customers or more significant pricing pressures
• Supply chain disruption might increase our production costs, limit our production capabilities or curtail our operations
• Our operations, and those of our suppliers, are subject to a variety of business continuity hazards and risks, any of which could interrupt production or operations or otherwise adversely affect our performance, results, or value
• Expectations relating to corporate responsibility considerations expose us to potential liabilities, increased costs, reputational harm and other adverse effects on our business
• We may be adversely affected by global climate change or by existing and future legal, regulatory or market responses to such change
• Our EO sterilization operations subject us to claims of liability and associated adverse effects
• A pandemic or similar public health crisis could have a material adverse impact on our ability to staff our operations
• Our business and results of operations may be adversely affected if we are unable to recruit and retain qualified management and other personnel
• Our debt level or access to credit markets may limit our financial and business flexibility
• Our investments in our business and product offerings may not be as successful as anticipated
• Our business realignment initiatives may not be as successful as anticipated
• Our acquisition activity and ability to grow organically may be adversely affected if we are unable to continue to access the financial markets
• The integration of acquired businesses into STERIS or working arrangements with joint venture partners may not be as successful as anticipated
• Past and future business acquisitions may not be as accretive to STERIS’s earnings per share and cash flow from operations per share, which may negatively affect the market price of STERIS shares
• STERIS has incurred and expects to incur significant transaction and related costs in connection with strategic transactions, which may be in excess of those anticipated
• We have recorded goodwill and other intangible assets that could become impaired and result in material non-cash charges to our results of operation in the future

Filings

Other Health Care companies